Article originally published in Competition Law Insight on November 25, 2008
May a dominant pharmaceutical company refuse to supply in full the orders it receives from a wholesaler in an EU member state in order to limit parallel trade in its products in the European Union? This was the question addressed by the European Court…
Article originally published in the Food and Drug Law Journal (with permission from FDLI), August 2008
I. INTRODUCTION
Pharmacovigilance is a global public health activity that is currently undergoing a considerable amount of regulatory, social and political change. The standards expected by society have been raised following high-profile product withdrawals. Industry, regulatory authorities and consumers…
Article originally published in RAJ Pharma in July 2008
By 2015 nanotechnology-based medicines and medical devices are expected to flood the global market. Brian Kelly and Peter Bogaert discuss the regulatory and legal implications of medical nanotechnology in Europe.
Nanotechnologies are the design, characterisation, production and application of structures, devices and systems by controlling shape and size…
